Herbal and plant therapy in patients with inflammatory bowel disease

Annals of Gastroenterology

Volumn 28, Issue 2, 2015, Pages 210-220

  Triantafyllidi, Aikaterini ^a   Xanthos, Theodoros ^a   Papalois, Apostolos ^b   Triantafillidis, John K ^c  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b ELPEN Pharmaceutical Experimental Laboratory   (Greece)

^c IASO GENERAL HOSPITAL   (Greece)

Author keywords

Alternative medicine; Crohn s disease; Herbal medicine; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

ACETYLSALICYLIC ACID; ANDROGRAPHIS PANICULATA EXTRACT; ANTHOCYANIN; ANTIINFLAMMATORY AGENT; BOSWELLIA SERRATA EXTRACT; CANNABIS; CHAMOMILE; CHINESE DRUG; CURCUMIN; DEXAMETHASONE; FISH OIL; FUFANGKUSHEN COLON; HERBACEOUS AGENT; JIAN PI LING; MESALAZINE; PLACEBO; PLANT EXTRACT; PLANT MEDICINAL PRODUCT; POTENTILLA ERECTA EXTRACT; PRIMROSE OIL; SALAZOSULFAPYRIDINE; TRIPTERYGIUM WILFORDII HOOK F; UNCLASSIFIED DRUG; XILEI SAN;

ABSENCE OF SIDE EFFECTS; ALOE VERA; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTEMISIA ABSINTHIUM; BLOATING; BOSWELLIA SERRATA; CONSTIPATION; CONTROLLED CLINICAL TRIAL (TOPIC); CROHN DISEASE; DOSE RESPONSE; DRUG CAPSULE; DRUG DOSE ESCALATION; DRUG SAFETY; EVENING PRIMROSE; GEL; GERMINATED BARLEY FOODSTUFF; HERBAL MEDICINE; HUMAN; INFLAMMATORY BOWEL DISEASE; IRRITABLE COLON; MAINTENANCE THERAPY; MULTICENTER STUDY (TOPIC); NAUSEA; PHYTOCHEMISTRY; PISTACIA LENTISCUS; PLANT LEAF; PLANT PRODUCT; PLANTAGO OVATA; PROCTITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM HEMORRHAGE; RECURRENT DISEASE; REMISSION; REVIEW; TREATMENT OUTCOME; TRIPTERYGIUM WILFORDII; TRITICUM AESTIVUM; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; VACCINIUM MYRTILLUS;

EID: 84926392755     PISSN: 11087471     EISSN: 17927463     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Triantafillidis JK, Stanciu C (eds). Inflammatory bowel disease: etiopathogenesis, diagnosis, treatment. 4th Edition, “Technogramma”, 2012 Athens, Greece.
2. Zollman C, Vickers A. What is complementary medicine? BMJ 1999;19:693-696.
3. Langmead L, Feakins RM, Goldthorpe S, et al. Randomized, double-blind, placebo-controlled trial of oral aloe vera gel for active ulcerative colitis. Aliment Pharmacol Ther 2004;19:739-747.
4. Ben-Arye E, Goldin E, Wengrower D, Stamper A, Kohn R, Berry E. Wheat grass juice in the treatment of active distal ulcerative colitis: a randomized double-blind placebo-controlled trial. Scand J Gastroenterol 2002;37:444-449.
5. Sandborn WJ, Targan SR, Byers VS, et al. Andrographis paniculata extract (HMPL-004) for active ulcerative colitis. Am J Gastroenterol 2013;108:90-98.
6. Tang T, Targan SR, Li ZS, Xu C, Byers VS, Sandborn WJ. Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis-a double-blind comparison with sustained release mesalazine. Aliment Pharmacol Ther 2010;33:194-202.
7. Abdel-Tawab M, Werz O, Schubert-Zsilavecz M. Boswellia serrata: an overall assessment of in vitro, preclinical, pharmacokinetic and clinical data. Clin Pharmacokinet 2011;50:349-369.
8. Gupta I, Parihar A, Malhotra P, et al. Effects of gum resin of Boswellia serrata in patients with chronic colitis. Planta Med 2001;67:391-395.
9. Chen ZS, Nie ZW, Sun QL. Clinical study in treating intractable ulcerative colitis with traditional Chinese medicine. Zhongguo Zhong Xi Yi Jie HeZa Zhi 1994;14:400-402.
10. Huber R, Ditfurth AV, Amann F, et al. Tormentil for active ulcerative colitis: an open-label, dose-escalating study. J Clin Gastroenterol 2007;41:834-838.
11. Zhang F, Li Y, Xu F, Chu Y, Zhao W. Comparison of Xilei-san, a chinese herbal medicine, and dexamethasone in mild/moderate ulcerative proctitis: a double-blind randomized clinical trial. J Altern Complement Med 2013;19:838-842.
12. Fukunaga K, Ohda Y, Hida N, et al. Placebo controlled evaluation of Xilei San, a herbal preparation in patients with intractable ulcerative proctitis. J Gastroenterol Hepatol 2012;27:1808-1815.
13. Biedermann L, Mwinyi J, Scharl M, et al. Bilberry ingestion improves disease activity in mild to moderate ulcerative colitis-an open pilot study. J Crohns Colitis 2013;7:271-279.
14. Gong Y, Zha Q, Li L, et al. Efficacy and safety of Fufangkushen colon-coated capsule in the treatment of ulcerative colitis compared with mesalazine: a double-blinded and randomized study. J Ethnopharmacol 2012;141:592-598.
15. Hanai H, Iida T, Takeuchi K, et al. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2006;4:1502-1506.
16. Fernandez-Banares F, Hinojosa J, Sanchez-Lombrana JL, et al. Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish group for the study of Crohn’s disease and ulcerative colitis (GETECCU). Am J Gastroenterol 1999;94:427-433.
17. Greenfield SM, Green AT, Teare JP, et al. A randomized controlled study of evening primrose oil and fish oil in ulcerative colitis. Aliment Pharmacol Ther 1993;7:159-166.
18. Hanai H, Kanauchi O, Mitsuyama K, et al. Germinated barley foodstuff prolongs remission in patients with ulcerative colitis. Int J Mol Med 2004;13:643-647.
19. Kanauchi O, Mitsuyama K, Homma T, et al. Treatment of ulcerative colitis patients by long-term administration of germinated barley foodstuff: multi-center open trial. Int J Mol Med 2003;12:701-704.
20. Langhorst J, Varnhagen I, Schneider SB, et al. Randomised clinical trial: a herbal preparation of myrrh, chamomile and coffee charcoal compared with mesalazine in maintaining remission in ulcerative colitis--a double-blind, double-dummy study. Aliment Pharmacol Ther 2013;38:490-500.
21. Kaliora AC, Stathopoulou MG, Triantafillidis JK, Dedoussis GV, Andrikopoulos NK. Chios mastic treatment of patients with active Crohn’s disease. World J Gastroenterol 2007;13:748-753.
22. Kaliora AC, Stathopoulou MG, Triantafillidis JK, Dedoussis GV, Andrikopoulos NK. Alterations in the function of circulating mononuclear cells derived from patients with Crohn’s disease treated with mastic. World J Gastroenterol 2007;13:6031-6036.
23. Omer B, Krebs S, Omer H, Noor TO. Steroid-sparing effect of wormwood (Artemisia absinthium) in Crohn’s disease: a double-blind placebo-controlled study. Phytomedicine 2007;14:87-95.
24. Krebs S, Omer TN, Omer B. Wormwood (Artemisia absinthium) suppresses tumour necrosis factor alpha and accelerates healing in patients with Crohn’s disease-a controlled clinical trial. Phytomedicine 2010;17:305-309.
25. Naftali T, Lev LB, Yablecovitch D, Half E, Konikoff FM. Treatment of Crohn’s disease with cannabis: an observational study. Isr Med Assoc J 2011;13:455-458.
26. Lal S, Prasad N, Ryan M, et al. Cannabis use amongst patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2011;23:891-896.
27. Gerhardt H, Seifert F, Buvari P, Vogelsang H, Repges R. Therapy of active Crohn disease with Boswellia serrata extract H15. Z Gastroenterol 2001;39:11-17.
28. Ren J, Tao Q, Wang X, Wang Z, Li J. Efficacy of T2 in active Crohn’s disease: a prospective study report. Dig Dis Sci 2007;52:1790-1797.
29. Holtmeier W, Zeuzem S, Preibeta J, et al. Randomized, placebo-controlled, double-blind trial of Boswellia serrata in maintaining remission of Crohn’s disease: good safety profile but lack of efficacy. Inflamm Bowel Dis 2010;17:573-582.
30. Tao QS, Ren JA, Ji ZL, Li JS, Wang XB, Jiang XH. Maintenance effect of polyglycosides of Tripterygium wilfordii on remission in postoperative Crohn disease. Zhonghua Wei Chang Wai KeZa Zhi 2009;12:491-493.
31. Liao NS, Ren JA, Fan CG, Wang GF, Zhao YZ, Li JS. Efficacy of polyglycosides of Tripterygium wilfordii in preventing postoperative recurrence of Crohn disease. Zhonghua Wei ChangWai Ke Za Zhi 2009;12:167-169.
32. Ren J, Wu X, Liao N, et al. Prevention of postoperative recurrence of Crohn’s disease: Tripterygium wilfordii polyglycoside versus mesalazine. J Int Med Res 2013;41:176-187.
33. Langhorst J, Anthonisen IB, Steder-Neukamm U, et al. Amount of systemic steroid medication is a strong predictor for the use of complementary and alternative medicine in patients with inflammatory bowel disease: results from a German national survey. Inflamm Bowel Dis 2005;11:287-295.
34. Langmead L, Chitnis M, Rampton DS. Use of complementary therapies by patients with IBD may indicate psychosocial distress. Inflamm Bowel Dis 2002;8:174-179.
35. Rahimi R, Mozaffari S, Abdollahi M. On the use of herbal medicines in management of inflammatory bowel diseases: a systematic review of animal and human studies. Dig Dis Sci 2009;54:471-480.
36. Ali T, Shakir F, Morton J. Curcumin and inflammatory bowel disease: biological mechanisms and clinical implication. Digestion 2012;85:249-255.
37. Dahmen U, Gu YL, Dirsch O, et al. Boswellic acid, a potent antiinflammatory drug, inhibits rejection to the same extent as high dose steroids. Transplant Proc 2001;33:539-541.
38. Singh P, Chacko KM, Aggarwal ML, et al. A-90 day gavage safety assessment of Boswellia serrata in rats. Toxicol Int 2012;19:273-278.
39. Bamba T, Kanauchi O, Andoh A, Fujiyama Y. A new prebiotic from germinated barley for nutraceutical treatment of ulcerative colitis. J Gastroenterol Hepatol 2002;17:818-824.
40. Cheng AL, Hsu CH, Lin JK, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001;21:2895-2900.
41. Anonymous. Safety of traditional Chinese medicines and herbal remedies. Curr Probl Pharmacovigilance 2004;30:10-11.
42. Triantafillidis JK. The use of natural products in the treatment of inflammatory bowel disease (Editorial). Ann Gastroenterol 2008;21:41-43.
43. Joos S. Review on efficacy and health services research studies of complementary and alternative medicine in inflammatory bowel disease. Chin J Integr Med 2011;17:403-409.